The Targeted Technology Fund II, like Fund I, is focused on early stage investments in companies that they believe can advance ground
Business Model:
Revenue: $15.4M
Employees: 11-50
Address: 18618 Tuscany Stone
City: San Antonio
State: TX
Zip: 78258
Country: US
The Targeted Technology Fund II, like Fund I, is focused on early stage investments in companies that they believe can advance ground breaking or disruptive technologies to significantly improve the practice of medicine and patient outcomes. They also favor technologies that can positively improve the efficiency, cost, or functionality of the development and manufacture of life science products.
Contact Phone:
+12105588896
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2014 | Bluegrass Vascular Technologies | Series A | 4.5M |
7/2009 | Vidacare | Series D | 7.6M |
2/2016 | Roxy’s Remedies | Series A | - |
4/2013 | ViroXis | Series A | 0 |
3/2016 | Aerin Medical | Series C | 16.7M |
10/2014 | DNAtriX | Series B | 20M |
1/2015 | Xenex | Venture Round | 0 |
6/2017 | neoSurgical | Series B | 5.5M |
11/2013 | Xenex | Venture Round | 0 |
11/2017 | Cardiovate | Seed | 1M |
4/2015 | StemBioSys | Series A | 8M |
3/2012 | Bi02 Medical | Series B | 0 |
9/2012 | Bi02 Medical | Series C | 0 |
11/2017 | Cardiovate | Seed Round | 0 |
6/2017 | neoSurgical | Series B | 0 |
3/2016 | Aerin Medical | Series C | 0 |
2/2016 | Roxy’s Remedies | Series A | - |
4/2015 | StemBioSys | Series A | 0 |
1/2015 | Xenex | Venture Round | 0 |
10/2014 | DNAtriX | Series B | 0 |
7/2014 | Bluegrass Vascular Technologies | Series A | 0 |
11/2013 | Xenex | Venture Round | 0 |
4/2013 | ViroXis | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|